KZIA Company Profile and Key Details

KZIA has shown mixed momentum, gaining 9.32% over the past week and 0.57% over the past quarter, though year-to-date performance is up 2.18%. Short-term trend indicators are bullishly aligned (SMA20 46.74%, SMA50 28.13%, SMA200 17.34%). The stock’s 14-day RSI is 69.24 (firm momentum), while the ATR of 0.87 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -49.14% below its high and over 209.44% above its low. Average 10-day trading volume of 216.22 thousand shares is slightly above the 3-month average of 189.84 thousand, indicating heightened recent market interest.

Kazia Therapeutics Limited generated EPS of -$12.31 over the past year. Five-year average earnings growth is 25.92%. Analyst sentiment is bullish. Analyst rating data shows there are 0 Strong Buy ratings, 6 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $25.00 to $13.00. The high target offers 164.27% upside. The low target suggests 37.42% downside. The mean target is $18.17. This offers 92.07% upside. Kazia Therapeutics Limited earnings surprise history is a mixed track record. The quarter that ended November 07, 2025, missed forecasts by 6529.86%. The prior quarter beat by 6529.71%. Over the last six quarters, Apple has recorded several small beats. These include 108.12% in November 19, 2024.

Kazia Therapeutics Limited has 1.36 million shares outstanding. The public float is 422.58 million shares, elevated short interest at 2.83% of float. This equals 31.07 thousand shares. The short ratio is 0.05 days. Institutional investors hold 9.73% of the float. Insiders own 8.48%.

Kazia Therapeutics Limited (NASDAQ:KZIA) closed at $10.40 USD, gaining $0.40 (4.00%) from the previous close of $10.00. The stock is currently mid-range between its 52-week high and low $2.86 and $17.40. With a market capitalization of about $16.85 million, Kazia Therapeutics Limited is classified as a micro-cap and shows higher-than-market volatility (beta ~1.62). Key stats such as the average daily volume over the past year has been around 229.75 thousand shares, volume is running light vs its 52-week average. Headquartered in Sydney, NSW, Kazia Therapeutics Limited operates in the Healthcare sector and the Biotechnology industry. Led by CEO John Edwin Friend, the company employs approximately 9 people and listed since January 06, 1999. Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops anti-cancer drugs.

Kazia Therapeutics Limited last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $2.55. This means the shares are trading above this model’s fair value.

Kazia Therapeutics Limited trades at a P/E ratio of -1.8, slightly below the S&P 500 average, with a price-to-sales ratio of 1055.61 and a price-to-book ratio of 0.86 suggesting the stock is closer to book value. The P/FCF stands at -2.29, also below market averages.

Our AI price prediction model suggests that Kazia Therapeutics Limited stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 2.85%, with price expected at $9.73 by April 28, 2026, within a range of $8.63 to $10.83 3-Month Outlook: Projected rise of 23.47%, reaching $11.68 by July 13, 2026, with a range of $9.56 to $13.48. 1-Year Outlook: Projected loss of -100.0%, with price at $0.00 by April 14, 2027, within a range of $0.00 to $6.93.

Kazia Therapeutics Limited (NASDAQ:KZIA) shares are flat 2.18% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Kazia Therapeutics Limited trading at a premium to the broader market with a P/E of -1.8. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $13.73, suggesting 45.14% upside. Our AI forecast model points to short-term strength (2.85% over two weeks), a medium-term rise (23.47% over three months), and a longer-term loss (-100.0% over one year), with expected trading ranges indicating moderate volatility.